Barclays Cuts Fortrea (NASDAQ:FTRE) Price Target to $12.00

Fortrea (NASDAQ:FTRE) had its price target decreased by Barclays from $15.00 to $12.00 in a research report sent to investors on Friday,Benzinga reports. Barclays currently has an equal weight rating on the stock.

FTRE has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fortrea in a research report on Thursday, January 22nd. Truist Financial set a $22.00 target price on Fortrea and gave the stock a “buy” rating in a research note on Thursday, January 8th. Wedbush set a $21.00 price target on Fortrea in a report on Thursday, December 11th. Mizuho set a $15.00 price objective on Fortrea in a research note on Friday, January 9th. Finally, TD Cowen boosted their price objective on Fortrea from $7.00 to $15.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Fortrea presently has an average rating of “Hold” and a consensus price target of $16.15.

Fortrea Stock Down 0.7%

Shares of NASDAQ:FTRE opened at $10.72 on Friday. The firm has a market capitalization of $1.00 billion, a PE ratio of -0.98, a price-to-earnings-growth ratio of 0.34 and a beta of 1.81. Fortrea has a 1 year low of $3.97 and a 1 year high of $18.67. The company has a debt-to-equity ratio of 1.86, a current ratio of 0.98 and a quick ratio of 0.98. The firm’s 50-day moving average is $15.14 and its two-hundred day moving average is $12.37.

Fortrea (NASDAQ:FTRE) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.07). Fortrea had a negative net margin of 36.21% and a positive return on equity of 6.23%. The business had revenue of $660.50 million during the quarter, compared to analyst estimates of $665.22 million. Analysts predict that Fortrea will post 0.51 EPS for the current year.

Institutional Trading of Fortrea

Several institutional investors have recently modified their holdings of FTRE. Invesco Ltd. grew its position in shares of Fortrea by 9.0% in the 4th quarter. Invesco Ltd. now owns 794,615 shares of the company’s stock valued at $13,707,000 after buying an additional 65,787 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Fortrea by 4.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 37,285 shares of the company’s stock valued at $643,000 after acquiring an additional 1,486 shares in the last quarter. Toronto Dominion Bank purchased a new position in shares of Fortrea during the fourth quarter worth about $51,000. Janus Henderson Group PLC acquired a new stake in shares of Fortrea during the fourth quarter worth about $789,000. Finally, Gotham Asset Management LLC purchased a new stake in shares of Fortrea in the 4th quarter valued at about $362,000.

Key Headlines Impacting Fortrea

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said full‑year revenue and adjusted EBITDA delivered in line with targets and that full‑year cost savings exceeded prior targets — a reassurance on operational execution. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
• Positive Sentiment: Robert W. Baird kept an “outperform” rating and a $16 price target (implying ~49% upside vs. current levels), signaling some analysts remain bullish on the company’s longer‑term outlook. Baird price target note
• Neutral Sentiment: Several full transcripts and earnings‑call highlights were published (useful for parsing management commentary and client/contract trends), giving investors primary‑source detail on drivers and margin dynamics. Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage remains active — a recent Benzinga roundup reviews seven ratings, which can amplify volatility as differing views are disseminated. Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
• Negative Sentiment: Q4 results missed consensus: reported EPS $0.09 vs. $0.16 expected, and revenue $660.5M vs. ~$665M expected — the headline misses are driving the immediate negative reaction. Fortrea Q4 Earnings and Revenues Lag Estimates (Zacks)
• Negative Sentiment: Barclays cut its price target to $12 and set an “equal weight” rating — a formal shift toward neutrality/less bullishness that can pressure sentiment and weaken near‑term buyer conviction. Barclays price target cut
• Negative Sentiment: FY‑2026 revenue guidance was given in a range (~$2.6B–$2.7B), which sits slightly below consensus at the top end — the cautious top‑line outlook and an unclear EPS guide left some investors wanting more upside visibility. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

About Fortrea

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.